ArticleTherapeutic advances in neurological disorders2025

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.

Miriam Freimer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.